Adaptive Biotechnologies Corp

Adaptive Biotechnologies announced its intention to pursue a separation of its Minimal Residual Disease (MRD) and Immune Medicine businesses, aiming to unlock potential and create shareholder value. The company will focus on its profitable MRD diagnostics business, while evaluating strategic alternatives for Immune Medicine by year-end 2026. Concurrently, Adaptive intends to offer $250 million in convertible senior notes due 2031, with proceeds primarily used to repay the OrbiMed Purchase Agreement ($156.9 million), fund capped call transactions, and repurchase up to $25 million of common stock.

Adaptive Biotechnologies Corporation announced its intention to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses. The company is evaluating strategic and structural alternatives for Immune Medicine to support its growth and value creation outside of Adaptive, expecting to identify a preferred path by year-end 2026. This move follows the establishment of both as separate operating segments in 2024, with MRD achieving significant scale and profitability, and Immune Medicine advancing its discovery platform.

Adaptive Biotechnologies Corporation announced its intention to offer $250 million in convertible senior notes due 2031 in a private offering. The company also expects to grant initial purchasers an option to buy an additional $37.5 million in notes. Proceeds from the offering are intended to repay the OrbiMed Purchase Agreement, repurchase up to $25 million of common stock, and fund general corporate purposes and initiatives in the MRD business. The company plans to enter into capped call transactions to mitigate potential dilution from the conversion of notes.

Adaptive Biotechnologies announced its clonoSEQ test will be featured in 33 presentations, including one plenary and 14 oral presentations, at the ASCO Annual Meeting and EHA Congress. These presentations reinforce clonoSEQ's role as the gold standard for assessing depth of response, longitudinal disease monitoring, and MRD-guided treatment decision-making in hematologic oncology. The data highlights its broad incorporation into research and clinical practice across multiple myeloma, CLL, ALL, and lymphoma, with growing global momentum for MRD-guided care.

Adaptive Biotechnologies Corporation announced its participation in two upcoming investor conferences. The company will host 1x1 meetings at the Craig-Hallum 23rd Annual Institutional Investor Conference on May 28th in Minneapolis. Additionally, Adaptive Biotechnologies will deliver a presentation at the William Blair 46th Annual Growth Stock Conference on June 3rd in Chicago, with a live and archived webcast available on its investor relations website.

Adaptive Biotechnologies Corp reported a significant improvement in its financial performance for the first quarter of 2026. The company saw a substantial increase in total revenue and a notable reduction in its net loss compared to the same period last year. This positive trend was primarily driven by strong growth in MRD revenue, despite a decrease in Immune Medicine revenue following the termination of the Genentech collaboration agreement.

Adaptive Biotechnologies reported strong first quarter 2026 financial results, with total revenue increasing 35% year-over-year to $70.9 million. The company's MRD business was a key driver, growing 53% to $67.1 million and contributing 95% of total revenue, alongside a 41% increase in clonoSEQ® test volume. Adaptive Biotechnologies also significantly reduced its net loss and Adjusted EBITDA loss compared to the prior year and raised its full year 2026 MRD revenue guidance to a new range of $260 million to $270 million.

Adaptive Biotechnologies Corp reported strong financial and operational results for 2025, with revenue increasing to $277.0 million, a 54.7% rise from 2024, primarily driven by its minimal residual disease (MRD) business which grew 46%. The company also significantly reduced net cash used in operations by 52% to $46.0 million. Additionally, Adaptive announced its 2026 Annual Meeting of Shareholders for June 5, 2026, where shareholders will vote on the election of two Class I directors, an advisory approval of executive compensation, and the ratification of Ernst & Young LLP as the independent registered public accounting firm.

Adaptive Biotechnologies Corp announced its 2026 Annual Meeting of Shareholders will be held virtually on June 5, 2026. Key proposals include the election of two Class I directors, an advisory vote on 2025 executive compensation, and the ratification of Ernst & Young LLP as the independent auditor for 2026. The company also highlighted strong 2025 financial performance, with revenue increasing to $277.0 million and a significant reduction in net cash used in operations.

Adaptive Biotechnologies Corporation announced it will report its financial results for the first quarter of 2026 after market close on Tuesday, May 5, 2026. Following the release, company management will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the results. The live audio webcast will be accessible via the "Investors" section of the company's website, with an archived replay available within 24 hours.